This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Magrolimab
DrugBank Accession Number
DB16225
Background

Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).

Type
Biotech
Groups
Investigational
Synonyms
  • Anti-cd47 monoclonal antibody hu5f9-g4
  • Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2
  • Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer
  • Magrolimab
External IDs
  • HU5F9 G4
  • Hu5F9-G4

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Magrolimab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Magrolimab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Magrolimab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Magrolimab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Magrolimab.
AmivantamabThe risk or severity of adverse effects can be increased when Magrolimab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Magrolimab.
AnsuvimabThe risk or severity of adverse effects can be increased when Magrolimab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Magrolimab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Magrolimab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
90YIEHRFJ9
CAS number
2169232-81-7

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentMyelodysplastic Syndromes (MDS)1
3RecruitingTreatmentAcute Myeloid Leukemia (AML)2
2RecruitingTreatmentClassic Hodgkin's Lymphoma / Lymphoma, Hodgkins / Refractory Classic Hodgkin Lymphoma / Relapsed Classical Hodgkin Lymphoma1
2RecruitingTreatmentMetastatic Colorectal Cancer (CRC)1
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentMyeloid Malignancy1
2RecruitingTreatmentSolid Tumors1
2RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentTriple Negative Breast Cancer1
1Active Not RecruitingTreatmentHaematological Malignancies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 15, 2020 18:16 / Updated at February 21, 2021 18:55